Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Wojciech Jurczak

Wojciech Jurczak

MD, PhD
Jagiellonian University
Improving the long-term safety of CLL treatment 0:58
Improving the long-term safety of CLL treatment
Wojciech Jurczak • 27 Sep 2024
Treating R/R CLL: the value of BTKis and venetoclax 1:59
Treating R/R CLL: the value of BTKis and venetoclax
Wojciech Jurczak • 27 Sep 2024
The potential of adding anti-CD20 antibodies to acalabrutinib and venetoclax in CLL 1:21
The potential of adding anti-CD20 antibodies to acalabrutinib and venetoclax in CLL
Wojciech Jurczak • 27 Sep 2024
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL 1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL 3:01
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
Wojciech Jurczak • 10 Jun 2023
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL 1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
Updates on tafasitamab for the treatment of DLBCL 1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022
Acalabrutinib in patients with CLL and MCL undergoing alloSCT 0:55
Acalabrutinib in patients with CLL and MCL undergoing alloSCT
Wojciech Jurczak • 11 Jun 2022
TIDAL and COASTAL: zandelisib for the treatment of R/R FL and MZL 2:41
TIDAL and COASTAL: zandelisib for the treatment of R/R FL and MZL
Wojciech Jurczak • 11 Jun 2022
LOXO-338 for the treatment of advanced hematological malignancies 0:41
LOXO-338 for the treatment of advanced hematological malignancies
Wojciech Jurczak • 11 Jun 2022
Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trial 1:08
Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trial
Wojciech Jurczak • 11 Jun 2022
Updates from the COSMOS trial: MOR208 for the treatment in R/R CLL 2:19
Updates from the COSMOS trial: MOR208 for the treatment in R/R CLL
Wojciech Jurczak • 14 Jun 2018
RELEVANCE study: the R-squared regimen for follicular lymphoma 3:21
RELEVANCE study: the R-squared regimen for follicular lymphoma
Wojciech Jurczak • 14 Jun 2018
Accessibility of CAR T-cell therapy 1:18
Accessibility of CAR T-cell therapy
Wojciech Jurczak • 14 Jun 2018
Avatrombopag: a novel oral therapy for the treatment of ITP 1:53
Avatrombopag: a novel oral therapy for the treatment of ITP
Wojciech Jurczak • 14 Jun 2018
MOR208: an effective drug for the treatment of CLL 0:32
MOR208: an effective drug for the treatment of CLL
Wojciech Jurczak • 22 Jun 2017
The content of VJHemOnc is intended for healthcare professionals